Urotensin II in Chronic Kidney Diseases and Kidney Transplants

This study has been completed.
Sponsor:
Information provided by (Responsible Party):
Mehmet Hursitoglu, Vakif Gureba Training and Research Hospital
ClinicalTrials.gov Identifier:
NCT01098799
First received: April 2, 2010
Last updated: June 12, 2013
Last verified: June 2013
  Purpose

The investigators are planning to study the serum level of Urotensin II in chronic kidney disease patients, kidney transplants, and healthy controls.


Condition
Chronic Renal Disease

Study Type: Observational
Study Design: Time Perspective: Prospective
Official Title: Urotensin II in Chronic Kidney Diseases

Resource links provided by NLM:


Further study details as provided by Vakif Gureba Training and Research Hospital:

Primary Outcome Measures:
  • serum Urotensin II(UII)level [ Time Frame: at enrollment ] [ Designated as safety issue: No ]
    We tried to compare UII level in normal, chronic kidney disease and kidney transplant patients group


Enrollment: 110
Study Start Date: April 2010
Study Completion Date: July 2010
Primary Completion Date: July 2010 (Final data collection date for primary outcome measure)
Groups/Cohorts
Control
Healthy controls
Chronic kidney disease-1
Chronic kidney disease not taking dialysis treatment
Kidney Transplant
Kidney transplants

Detailed Description:

The investigators will determine the urotensin II levels in Chronic kidney disease patients, kidney transplants, and healthy controls.

  Eligibility

Ages Eligible for Study:   18 Years to 90 Years
Genders Eligible for Study:   Both
Accepts Healthy Volunteers:   Yes
Sampling Method:   Non-Probability Sample
Study Population

Healthy controls,CRF patients and kidney transplants aged more than 18

Criteria

Inclusion Criteria:

  • Age more than 18

Exclusion Criteria:

  • Inability to give a written consent
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its ClinicalTrials.gov identifier: NCT01098799

Locations
Turkey
Vakif Gureba Training & Research Hospital
Istanbul, Turkey, 34100
Sponsors and Collaborators
Vakif Gureba Training and Research Hospital
Investigators
Study Director: Tufan Tukek, MD Vakif Gureba Training & Research Hospital
  More Information

No publications provided

Responsible Party: Mehmet Hursitoglu, Chair, Vakif Gureba Training and Research Hospital
ClinicalTrials.gov Identifier: NCT01098799     History of Changes
Other Study ID Numbers: Dahiliye-2-Urotensin
Study First Received: April 2, 2010
Last Updated: June 12, 2013
Health Authority: Turkey: Ministry of Health

Keywords provided by Vakif Gureba Training and Research Hospital:
Urotensin II,Chronic renal disease

Additional relevant MeSH terms:
Kidney Diseases
Kidney Failure, Chronic
Renal Insufficiency, Chronic
Urologic Diseases
Renal Insufficiency

ClinicalTrials.gov processed this record on August 01, 2014